aoncology.com - AONC Operating profit EBITDA
American Oncology Network generates revenue by providing IT infrastructure and administrative support to private oncology centers in the US. The EBITDA level reflects cash flow dynamics, where the value of describes the current yield. Stability is driven by inelastic demand and favorable bulk drug procurement, while niche regional concentration risks are mitigated through the implementation of centralized pharmacy services.
Summary analytical data breakdowns for American Oncology Network (AONC)
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
Total Debt to Capital American Oncology Network|AONC - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio AON|AONC - Company Aggregate Debts|Debts to Book Value American Oncology Network Inc|AONC - Company Long-Term Debt|Company Short-Term Loans and Borrowings American Oncology Network|Interim Coverage Ratio aoncology.com
- earnings and market ratios statistics:
AONC - Net Profit|Future Profit American Oncology Network|AONC - P/E Multiple|Forward P/E Multiple American Oncology Network|AONC - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation AON|AONC - Operating profit before deduction of amortization|Earnings per share for the trailing year American Oncology Network|AONC - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months aoncology.com|AONC - Earnings per share growth in current year|Projected earnings per share growth rate for next year American Oncology Network
- sales revenue and business income indicators:
Summary company analytics:American Oncology Network
This indicator captures the actual cash flow from operating activities before depreciation, allowing for an assessment of cash generation efficiency net of operating expenses. The implementation of AI analytics and document workflow automation at American Oncology Network (AONC) reduces administrative costs, which is reflected in the positive trend of gross operating profit before depreciation and confirms the high capital resilience of the issuer.
Competitors of American Oncology Network (AONC)
Operating profit EBITDA beigene.com ONC|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Corp - Income before deduction of interest, taxes and amortization|URGN (UroGen Pharma Ltd) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Therapeutics Inc. BCAX|Profit before payment of interest, taxes and amortization Personalis, Inc. (PSNL)|ERAS - Profit before interest, taxes and amortization|Operating profit EBITDA DCTH (delcath.com)|Operating profit before depreciation charges Y-mAbs Corp|AURA - Profit before payment of interest, taxes and amortization|CADL (candeltx.com) - Operating profit before amortization|ARAY (accuray.com) - Operating profit before deduction of amortization|SELLAS Life Sciences Group Inc. (SLS) - Operating profit EBITDA|ACTU (Actuate Therapeutics Inc.) - Operating profit EBITDA|Operating profit EBITDA Citius Oncology Inc|Operating profit EBITDA HURA|TARA (Protara Therapeutics) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA FATE (Fate Therapeutics)|Operating income before deduction of amortization Aadi Bioscience Inc (WHWK)|TScan Therapeutics, Inc. - Operating profit EBITDA|CSBR (Champions Oncology, Inc.) - Operating profit before amortization|XBIT (XBiotech USA) - Operating profit before deduction of amortization|Profit before interest, taxes and amortization CEL-SCI Corp (CVM)|OSTX (OS Therapies Inc.) - Operating profit EBITDA|Operating profit before deduction of amortization Radiopharm Theranostics (RADX)|Operating profit before deduction of amortization ARTV (Artiva Biotherapeutics, Inc.)|ANL - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Veru Inc. VERU|Income before deduction of interest, taxes and amortization TPST|XLO: Operating profit before deduction of amortization|Operating income before deduction of amortization Renovaro RENB|MURA (muraloncology.com) - Operating profit before deduction of amortization|Kairos Pharma Inc - Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization OKUR|Profit before interest, taxes and amortization CytoMed Therapeutics Limited GDTC|Operating profit EBITDA CRIS|Operating profit EBITDA Apollomics Inc. (APLM)|Operating profit EBITDA THAR (Tharimmune Corp)|Operating income before deduction of amortization Advanced Biomed Inc (ADVB)|Genprex Inc - Operating profit EBITDA|CLDI - Operating profit EBITDA|Sunshine Biopharma Inc. (SBFM) - Profit before payment of interest, taxes and amortization|XBIO - Operating income before deduction of amortization|SLRX (Salarius Pharma) - Operating profit EBITDA|Operating profit EBITDA Kitov Pharma|Operating profit EBITDA BGNE|Operating income before deduction of amortization Checkpoint Therapeutics|Elevation Oncology, Inc. - Operating profit before deduction of amortization|Operating profit EBITDA iCAD, Inc. ICAD|Ikena Oncology, Inc. - Operating profit EBITDA|NTBL - Operating profit EBITDA|VIRX (Viracta Therapeutics) - Operating profit before deduction of amortization|MorphoSys AG - Income before deduction of interest, taxes and amortization|NAYA (NAYA Biosciences Corp) - Operating profit EBITDA|Operating profit EBITDA Ascentage Pharma Group International
